Garland, Nilda
Garland, Nilda was paid $433K by Medicaid between Jan 2018 and Dec 2024, across 45 billing codes. Its largest line is 84443, Thyroid stimulating hormone (TSH) — 19% of everything it billed.
33Billing provider infoGARLAND, NILDA
COAMO, PR 00769
COAMO, PR 00769
33aNPI1790725109assigned 06/07/2006
33bProvider typeOther Specialist/Technologist
28Total paid$433K
24GClaims44,133
24DCodes billed45
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,023 | $47K | |
| 2019 | 4,839 | $36K | |
| 2020 | 3,680 | $29K | |
| 2021 | 5,806 | $58K | |
| 2022 | 7,029 | $80K | |
| 2023 | 8,794 | $92K | |
| 2024incomplete | 7,962 | $91K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 84443 | Thyroid stimulating hormone (TSH) | 19% | 5,420 | 5,181 | $82K |
| 80061 | Lipid panel | 16% | 5,584 | 5,331 | $69K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 9.9% | 6,520 | 6,065 | $43K |
| 80053 | Comprehensive metabolic panel | 9.3% | 4,277 | 4,034 | $40K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.1% | 1,007 | 942 | $35K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.1% | 820 | 757 | $22K |
| 81000 | 5.1% | 7,134 | 6,678 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 4.7% | 2,321 | 2,195 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.5% | 2,549 | 2,459 | $19K |
| 82274 | 1.9% | 587 | 546 | $8K | |
| 82607 | 1.5% | 470 | 433 | $7K | |
| 84153 | 1.5% | 415 | 392 | $7K |
33 more codes
| 86701 | 1.4% | 787 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 181 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.4% | 466 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 166 | $6K |
| 87088 | 1.2% | 701 | $5K | |
| 82044 | 1.1% | 1,180 | $5K | |
| 84439 | 1.1% | 556 | $5K | |
| 86328 | <1% | 149 | $3K | |
| 86738 | <1% | 219 | $3K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 160 | $2K |
| 85651 | <1% | 471 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 60 | $1K |
| 86592 | <1% | 368 | $1K | |
| 86803 | <1% | 105 | $1K | |
| 82043 | <1% | 218 | $1K | |
| 82570 | <1% | 202 | $978.36 | |
| 84436 | <1% | 144 | $799.03 | |
| 80050 | General health panel | <1% | 63 | $552.67 |
| 84550 | <1% | 115 | $499.85 | |
| 85730 | <1% | 60 | $339.14 | |
| 82947 | <1% | 95 | $318.98 | |
| 84478 | <1% | 55 | $296.01 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 181 | $284.66 |
| 82465 | <1% | 66 | $266.41 | |
| 85610 | <1% | 72 | $255.62 | |
| 82270 | <1% | 63 | $191.80 | |
| 87275 | <1% | 12 | $136.66 | |
| 87276 | <1% | 12 | $136.66 | |
| 83655 | <1% | 12 | $128.36 | |
| 84460 | <1% | 25 | $69.82 | |
| 84450 | <1% | 25 | $69.67 | |
| 81001 | <1% | 25 | $42.84 | |
| 87899 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.